January 13, 2023
RegMed Investors’ (RMi) pre-open: vulnerable?
January 12, 2023
RegMed Investors’ (RMi) pre-open: the cell/gene therapy sector reminds me of Abbott & Costello
January 11, 2023
RegMed Investors’ (RMi) pre-open: Day #3 of JPMorgan healthcare conference; All Quiet on the West Coast
January 10, 2023
RegMed Investors’ (RMi) pre-open: after a lackluster first day at JPM23 with smaller attendance, NO masks and a diving sector
January 9, 2023
RegMed Investors’ (RMi) pre-open: will JPM23 stimulate or just ripple share pricing?
January 6, 2023
RegMed Investors’ (RMi) pre-open: wait for it
January 5, 2023
RegMed Investors’ (RMi) pre-open: who says economics doesn’t affect the cell and gene therapy sector?
January 4, 2023
RegMed Investors’ (RMi) pre-open: a dash of strength
January 3, 2023
RegMed Investors’ (RMi) pre-open: Expectation will be the word for 2023
December 30, 2022
RegMed Investors’ (RMi) pre-open: end it on a positive note and good-bye to 2022 sessions
December 29, 2022
RegMed Investors’ (RMi) pre-open: risk-on/risk-off sessions based on market’s insecurity, sector’s pricing uncertainty in an overcrowded universe
December 28, 2022
RegMed Investors’ (RMi) pre-open: a holiday shortened week
December 27, 2022
RegMed Investors’ (RMi) pre-open: roaming and ranging, not today
December 23, 2022
RegMed Investors’ (RMi) pre-open: awaiting the holiday and the Fed
December 22, 2022
RegMed Investors’ (RMi) pre-open: another shift to caution, there's still the risk that this is another trap to lure investors in just before a pullback
December 21, 2022
RegMed Investors’ (RMi) pre-open: a follow through for positive sector equities?
December 20, 2022
RegMed Investors’ (RMi) pre-open: time to cut further back on already reduced risk exposure
December 19, 2022
RegMed Investors’ (RMi) pre-open: a Santa Claus bounce after recent sell-off
December 16, 2022
RegMed Investors’ (RMi) pre-open finally Friday
December 15, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector suffered from indigestion post Jerome’s rate gospel
December 14, 2022
RegMed Investors’ (RMi) pre-open: waiting for Jerome’s latest interest rate hike decision
December 13, 2022
RegMed Investors’ (RMi) pre-open: been waiting to exhale - ha
December 12, 2022
RegMed Investors’ (RMi) pre-open: wait or take a risky shot at the oversold rolling up?
December 9, 2022
RegMed Investors’ (RMi) pre-open: December ain’t turning-out, so far to be a good month for the cell and gene therapy sector –up against resistance
December 8, 2022
RegMed Investors’ (RMi) pre-open: climbing the wall of worry
7 hours 4 min ago
RMi Closing Bell: Barely
16 hours 33 min ago
RMi pre-open: Skepticism
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.